Neurovance Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $250M

Neurovance General Information

Description

Developer of a triple re-uptake inhibitor designed to address lack of focus, inattention and disorganization in ADHD patients. The company's triple re-uptake inhibitor Centanafadine (CTN) modulates the activity of norepinephrine, dopamine and serotonin in a specific ratio to affect a specific result, helping patients with ADHD, attention-deficit hyperactivity disorder.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 43 Thorndike Street
  • Suite S1-3
  • Cambridge, MA 02141
  • United States
Primary Industry
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 43 Thorndike Street
  • Suite S1-3
  • Cambridge, MA 02141
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurovance Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 01-Mar-2017 $250M Completed Clinical Trials - Phase 3
4. Early Stage VC 29-Feb-2016 Completed Clinical Trials - Phase 3
3. Early Stage VC (Series A1) 29-Jun-2015 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A1) 14-Mar-2014 $10.5M $11M Completed Startup
1. Early Stage VC (Series A) 30-May-2012 $478K $478K Completed Startup
To view Neurovance’s complete valuation and funding history, request access »

Neurovance Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A
To view Neurovance’s complete cap table history, request access »

Neurovance Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a triple re-uptake inhibitor designed to address lack of focus, inattention and disorganization in ADHD pat
Drug Discovery
Cambridge, MA
6 As of 2014

Lexington, MA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurovance Competitors (10)

One of Neurovance’s 10 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Formerly VC-backed Lexington, MA
Curemark Venture Capital-Backed New York, NY
T3D Therapeutics Venture Capital-Backed Durham, NC
Alzheon Venture Capital-Backed Framingham, MA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
You’re viewing 5 of 10 competitors. Get the full list »

Neurovance Patents

Neurovance Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2017502948-A Novel composition Inactive 09-Dec-2013
AU-2014374259-A1 Novel compositions Inactive 09-Dec-2013
CA-2936108-A1 Novel compositions Inactive 09-Dec-2013
EP-3080080-A1 Novel compositions Inactive 09-Dec-2013
EP-3080080-A4 Novel compositions Inactive 09-Dec-2013 A61K31/403
To view Neurovance’s complete patent history, request access »

Neurovance Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurovance Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Clarevia Ventures Venture Capital Minority
GBS Venture Partners Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
State of Wisconsin Investment Board Government Minority
abrdn Healthcare Investors Hedge Fund Minority
To view Neurovance’s complete investors history, request access »

Neurovance FAQs

  • When was Neurovance founded?

    Neurovance was founded in 2011.

  • Where is Neurovance headquartered?

    Neurovance is headquartered in Cambridge, MA.

  • What is the size of Neurovance?

    Neurovance has 6 total employees.

  • What industry is Neurovance in?

    Neurovance’s primary industry is Drug Discovery.

  • Is Neurovance a private or public company?

    Neurovance is a Private company.

  • What is the current valuation of Neurovance?

    The current valuation of Neurovance is .

  • What is Neurovance’s current revenue?

    The current revenue for Neurovance is .

  • How much funding has Neurovance raised over time?

    Neurovance has raised $45.5M.

  • Who are Neurovance’s investors?

    Clarevia Ventures, GBS Venture Partners, Novartis Venture Fund, State of Wisconsin Investment Board, and abrdn Healthcare Investors have invested in Neurovance.

  • Who are Neurovance’s competitors?

    Voyager Therapeutics, Curemark, T3D Therapeutics, Alzheon, and Vertex Pharmaceuticals are some of the 10 competitors of Neurovance.

  • When was Neurovance acquired?

    Neurovance was acquired on 01-Mar-2017.

  • Who acquired Neurovance?

    Neurovance was acquired by Otsuka Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process